LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 86

Search options

  1. Article: Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer.

    Kota, Karthik / Puhalla, Shannon

    Cureus

    2017  Volume 9, Issue 7, Page(s) e1424

    Abstract: Triple-negative breast cancers (TNBC) have poorer outcomes than hormone positive or human epidermal growth factor receptor 2 (HER2)-positive breast cancers, with chemotherapy being the usual standard of care. Veliparib, a poly ADP-ribose polymerase (PARP) ...

    Abstract Triple-negative breast cancers (TNBC) have poorer outcomes than hormone positive or human epidermal growth factor receptor 2 (HER2)-positive breast cancers, with chemotherapy being the usual standard of care. Veliparib, a poly ADP-ribose polymerase (PARP) inhibitor, has been studied in both breast cancer susceptibility genes 1 and 2 (BRCA)-mutation related and sporadic cancers as a single agent and in combination with chemotherapy. Here, we describe a patient whose metastatic recurrence of TNBC was treated with combination chemotherapy and veliparib followed by maintenance single-therapy veliparib.
    Language English
    Publishing date 2017-07-04
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2747273-5
    ISSN 2168-8184
    ISSN 2168-8184
    DOI 10.7759/cureus.1424
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: PARP inhibitors: what we know and what we have yet to know.

    Puhalla, Shannon

    Oncology (Williston Park, N.Y.)

    2010  Volume 24, Issue 1, Page(s) 62, 65–6

    MeSH term(s) BRCA1 Protein/genetics ; BRCA1 Protein/metabolism ; BRCA2 Protein/genetics ; BRCA2 Protein/metabolism ; Breast Neoplasms/drug therapy ; Breast Neoplasms/enzymology ; Breast Neoplasms/genetics ; Clinical Trials as Topic ; Enzyme Inhibitors/pharmacology ; Female ; Humans ; Poly(ADP-ribose) Polymerases/physiology
    Chemical Substances BRCA1 Protein ; BRCA2 Protein ; Enzyme Inhibitors ; Poly(ADP-ribose) Polymerases (EC 2.4.2.30)
    Language English
    Publishing date 2010-01
    Publishing country United States
    Document type Comment ; Journal Article ; Review
    ZDB-ID 1067950-9
    ISSN 0890-9091
    ISSN 0890-9091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3168: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 372: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial.

    Diéras, Véronique / Han, Hyo S / Wildiers, Hans / Friedlander, Michael / Ayoub, Jean-Pierre / Puhalla, Shannon L / Loirat, Delphine / Ratajczak, Christine / Adamu, Hephzibah / Girardi, Vincent / Arun, Banu K

    European journal of cancer (Oxford, England : 1990)

    2024  Volume 200, Page(s) 113580

    Abstract: Background: In the BROCADE3 study, the addition of veliparib to carboplatin plus paclitaxel resulted in a significant improvement in progression-free survival (PFS) compared with placebo plus carboplatin and paclitaxel, in patients with germline BRCA1 ... ...

    Abstract Background: In the BROCADE3 study, the addition of veliparib to carboplatin plus paclitaxel resulted in a significant improvement in progression-free survival (PFS) compared with placebo plus carboplatin and paclitaxel, in patients with germline BRCA1 or BRCA2 (BRCA1/2)-mutated, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We now report final overall survival (OS) data.
    Methods: BROCADE3 is a randomized phase 3 study that enrolled patients with BRCA1/2-mutated, HER2-negative advanced breast cancer who received ≤ 2 prior lines of chemotherapy for metastatic disease. Patients were randomized 2:1 to carboplatin and paclitaxel, dosed with either veliparib or matching placebo. OS was a secondary endpoint.
    Results: In the intention-to-treat population (N = 509), 337 patients were randomized to receive veliparib and 172 to placebo. Median OS was 32.4 months vs 28.2 months (hazard ratio, 0.916; 95% CI, 0.736-1.140; P = .434). The updated safety data for veliparib are consistent with those reported in the primary analysis; the addition of veliparib was generally well tolerated.
    Conclusions: Final OS data indicate that the PFS improvement shown in the primary analysis did not translate into an OS benefit. The long survival times observed in both arms suggest that combination therapy with paclitaxel and carboplatin provides clinical benefit in the population of patients with BRCA1/2-mutated metastatic breast cancer.
    MeSH term(s) Humans ; Female ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Carboplatin ; Paclitaxel ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Benzimidazoles
    Chemical Substances Carboplatin (BG3F62OND5) ; Paclitaxel (P88XT4IS4D) ; BRCA1 protein, human ; BRCA1 Protein ; veliparib (01O4K0631N) ; BRCA2 protein, human ; BRCA2 Protein ; Benzimidazoles
    Language English
    Publishing date 2024-01-28
    Publishing country England
    Document type Randomized Controlled Trial ; Clinical Trial, Phase III ; Journal Article
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2024.113580
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Breast cancer: The 21-gene recurrence score - biology remains at the forefront.

    Puhalla, Shannon L / Davidson, Nancy E

    Nature reviews. Clinical oncology

    2016  Volume 13, Issue 8, Page(s) 470–472

    Language English
    Publishing date 2016-08
    Publishing country England
    Document type Journal Article
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/nrclinonc.2016.98
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6029: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 103: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Management of breast cancer brain metastases is moving forward, but new options are still needed.

    Pahuja, Shalu / Puhalla, Shannon

    Oncology (Williston Park, N.Y.)

    2014  Volume 28, Issue 7, Page(s) 585, 590–2

    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Brain Neoplasms/drug therapy ; Brain Neoplasms/secondary ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Female ; Humans
    Language English
    Publishing date 2014-07
    Publishing country United States
    Document type Comment ; Journal Article
    ZDB-ID 1067950-9
    ISSN 0890-9091
    ISSN 0890-9091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3168: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 372: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Erratum to Metaplastic Breast Carcinoma: A Clinical-Pathologic Study of 97 Cases With Subset Analysis of Response to Neoadjuvant Chemotherapy [Modern Pathology 32(6) (2019) 807-816].

    Han, Min / Salamat, Arsalan / Zhu, Li / Zhang, Huina / Clark, Beth Z / Dabbs, David J / Carter, Gloria J / Brufsky, Adam M / Jankowitz, Rachel C / Puhalla, Shannon L / Johnson, Ronald R / Soran, Atilla / Steiman, Jennifer G / McAuliffe, Priscilla F / Diego, Emilia J / Bhargava, Rohit

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

    2023  Volume 36, Issue 8, Page(s) 100267

    Language English
    Publishing date 2023-07-13
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 645073-8
    ISSN 1530-0285 ; 0893-3952
    ISSN (online) 1530-0285
    ISSN 0893-3952
    DOI 10.1016/j.modpat.2023.100267
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2450: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).

    Geyer, Charles E / Blum, Joanne L / Yothers, Greg / Asmar, Lina / Flynn, Patrick J / Robert, Nicholas J / Hopkins, Judith O / O'Shaughnessy, Joyce A / Rastogi, Priya / Puhalla, Shannon L / Hilton, Christie J / Dang, Chau T / Gómez, Henry Leonidas / Vukelja, Svetislava J / Lyss, Alan P / Paul, Devchand / Brufsky, Adam M / Colangelo, Linda H / Swain, Sandra M /
    Mamounas, Eleftherios P / Wolmark, Norman

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2024  Volume 42, Issue 12, Page(s) 1344–1349

    Abstract: Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial ... ...

    Abstract Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in
    MeSH term(s) Humans ; Female ; Taxoids/therapeutic use ; Follow-Up Studies ; Breast Neoplasms/drug therapy ; Anthracyclines ; Hormones ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
    Chemical Substances Taxoids ; Anthracyclines ; Hormones
    Language English
    Publishing date 2024-02-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.23.01428
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.

    Burgess, Melissa / Puhalla, Shannon

    Frontiers in oncology

    2014  Volume 4, Page(s) 19

    Abstract: No longer is histology solely predictive of cancer treatment and outcome. There is an increasing influence of tumor genomic characteristics on therapeutic options. Both breast and ovarian cancers are at higher risk of development in patients with BRCA 1/ ... ...

    Abstract No longer is histology solely predictive of cancer treatment and outcome. There is an increasing influence of tumor genomic characteristics on therapeutic options. Both breast and ovarian cancers are at higher risk of development in patients with BRCA 1/2-germline mutations. Recent data from The Cancer Genome Atlas and others have shown a number of genomic similarities between triple negative breast cancers (TNBCs) and ovarian cancers. Recently, poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in hereditary BRCA 1/2-mutated and sporadic breast and ovarian cancers. In this review, we will summarize the current literature regarding the genomic and phenotypic similarities between BRCA 1/2-mutation related cancers, sporadic TNBCs, and sporadic ovarian cancers. We will also review Phase I, II, and III data using PARP inhibitors for these malignancies and compare and contrast the results with respect to histology.
    Language English
    Publishing date 2014-02-27
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2014.00019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Triple-negative breast cancer: not entirely negative.

    Leone, José Pablo / Puhalla, Shannon

    Oncology (Williston Park, N.Y.)

    2013  Volume 27, Issue 9, Page(s) 856, 858–9

    MeSH term(s) Animals ; Antineoplastic Agents/therapeutic use ; Female ; Humans ; Molecular Targeted Therapy ; Signal Transduction/drug effects ; Triple Negative Breast Neoplasms/drug therapy
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2013-09
    Publishing country United States
    Document type Comment ; Journal Article
    ZDB-ID 1067950-9
    ISSN 0890-9091
    ISSN 0890-9091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3168: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 372: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Treatment of HER2-positive breast cancer: looking backwards briefly.

    Puhalla, Shannon / Brufsky, Adam

    The Lancet. Oncology

    2013  Volume 14, Issue 13, Page(s) 1250–1251

    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Biomarkers, Tumor/analysis ; Breast Neoplasms/drug therapy ; Female ; Humans ; Mastectomy ; Neoadjuvant Therapy/methods ; Receptor, ErbB-2/analysis
    Chemical Substances Biomarkers, Tumor ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1)
    Language English
    Publishing date 2013-11-13
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(13)70536-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5696: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 460: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top